What is Evofem?
Evofem Biosciences, Inc. is dedicated to commercializing innovative products designed to address critical unmet needs within women's sexual and reproductive health. The company's commitment lies in developing and delivering better choices for women, targeting markets with substantial unmet needs and accelerating the availability of these solutions. Their focus on innovation and patient-centricity positions them as a key player in advancing women's healthcare.
How much funding has Evofem raised?
Evofem has raised a total of $154.8M across 6 funding rounds:
Private Equity
$25M
Series C
$20.6M
Series D
$25M
Other Financing Round
$80M
Stock Offering
$3.3M
Private Equity
$925K
Private Equity (2009): $25M with participation from Undisclosed
Series C (2012): $20.6M led by AMOREPACIFIC US, Alta Partners, RMI Partners, and RUSNANO
Series D (2016): $25M supported by Woodford Investment Management
Other Financing Round (2019): $80M featuring PDL, Woodford Investment Management, and Invesco Asset Management
Stock Issuance/Offering (2024): $3.3M backed by Aditx
Private Equity (2025): $925K, investors not publicly disclosed
Key Investors in Evofem
Woodford Investment Management
Woodford Investment Management is a financial services firm that managed various investment funds. The company has faced regulatory challenges and has seen changes in management for its funds, with new investment managers appointed for some of them.
Invesco Asset Management
Invesco Ltd. is a publicly owned investment manager providing services to retail and institutional clients. The firm manages separate client-focused equity and fixed income portfolios and launches various mutual and exchange-traded funds.
Aditx
Aditxt, Inc.® is a social innovation platform dedicated to accelerating promising health innovations. Aditxts ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to Make Promising Innovations Possible Together.
What's next for Evofem?
The recent major strategic investment signals a pivotal growth phase for Evofem. This capital infusion is expected to fuel further product development, expand market reach, and enhance commercialization efforts. With a clear focus on addressing significant unmet needs in women's health, Evofem is poised to leverage this financing to solidify its market position and continue its trajectory of innovation and impact in the reproductive health sector.
See full Evofem company page
